Allergan Plc (AGN) 238.28 $AGN
Allergan Demonstrates a Strong Commitment to America's First Responders Donating Over $1 Million Worth of REFRESH® Eye Drops
PR Newswire - Thu Jul 07, 7:05AM CDT
Allergan plc is pleased to announce that it is leading the effort to alleviate discomfort of dry eye symptoms for America's heroes and has exceeded its goal of donating $1 million worth of REFRESH® eye drops to our nation's first responders. Last summer, Allergan kicked off the REFRESH AMERICA campaign aiming to help everyday heroes alleviate their discomfort from dry eye symptoms brought on by exposure to elements like heat, wind, smoke and dust which are inherent to their work. Every purchase of specially-marked packages in the REFRESH OPTIVE® product line since August 2015 has led to over eighty thousand donations of REFRESH® eye drops to first responder groups nationwide.
AGN: 238.28 (-2.31)
AstraZeneca Skin Drug, Tralokinumab, Rights Licensed to LEO
Arpita Dutt - Zacks Investment Research - Wed Jul 06, 8:39AM CDT
AstraZeneca (AZN) out-licensed global rights to tralokinumab for skin diseases to LEO Pharma.
AGN: 238.28 (-2.31), VRX: 23.09 (-0.16), AZN: 29.97 (-0.14), AMGN: 160.18 (-0.92)
Revance Appoints Industry Leader Julian S. Gangolli to its Board of Directors
BusinessWire - Tue Jul 05, 7:00AM CDT
Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Julian S. Gangolli, President, North America, of GW Pharmaceuticals plc, has been elected to Revance's Board of Directors and will serve as a member of the Audit Committee, effective July 1, 2016.
AGN: 238.28 (-2.31), RVNC: 13.25 (-0.04)
Allergan Receives Positive Opinion Through European Decentralised Procedure For BELKYRA® (Deoxycholic Acid) For Patients With Submental Fullness
PR Newswire Europe - Fri Jul 01, 6:30AM CDT
-- BELKYRA((R)) (deoxycholic acid) expected to be the first non-surgical prescription medicine to treat submental fullness (or double chin) to be authorised in 21 European Union Member States as well as Iceland and Norway --
AGN: 238.28 (-2.31)
New Global Research from Allergan Shows New Attitude to Beauty as Women Seek Confidence Over Youth
PR Newswire Europe - Fri Jul 01, 3:43AM CDT
DUBLIN and MARLOW, England, July 1, 2016 /PRNewswire/ --
AGN: 238.28 (-2.31)
New Global Research From Allergan Shows New Attitude To Beauty As Women Seek Confidence Over Youth
PR Newswire Europe - Tue Jun 28, 6:01AM CDT
-- First and largest of its kind research captures the attitudes of nearly 8,000 women across 16 countries and identifies a new age of beauty confidence(1)
AGN: 238.28 (-2.31)
After Yesterday's Decline of 2.88%, Allergan Offers Investors Better Value
Comtex SmarTrend(R) - Mon Jun 27, 12:18PM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $217.67 to a high of $225.87. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $225.40 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 238.28 (-2.31)
Teva's Cinqaero Gets Positive CHMP View, Decision in 2H16
Arpita Dutt - Zacks Investment Research - Mon Jun 27, 7:10AM CDT
Teva's (TEVA) asthma treatment, Cinqaero, which is already available in the U.S., got a positive CHMP opinion.
AGN: 238.28 (-2.31), PFE: 36.15 (+0.03), TEVA: 50.93 (+0.04), AMPH: 16.94 (+0.14)
Allergan (AGN) Gets FDA Nod for Avycaz Label Expansion
Arpita Dutt - Zacks Investment Research - Fri Jun 24, 8:12AM CDT
Allergan (AGN) is working on expanding the label of several of its approved products.
AGN: 238.28 (-2.31), PFE: 36.15 (+0.03), TEVA: 50.93 (+0.04), AMPH: 16.94 (+0.14)
Why Pfizer (PFE) is a Great Stock to Buy for the Long Run
Maher Syed - Zacks Investment Research - Thu Jun 23, 7:37PM CDT
Pfizer has a great dividend, and it generates an incredibly high level of sales, but here's why else this stock is worth keeping in your portfolio for the long haul.
AGN: 238.28 (-2.31), PFE: 36.15 (+0.03), ANAC: 99.06 (-0.14)
Millendo Therapeutics Appoints New Independent Board Member and Names Chairperson of the Board
BusinessWire - Thu Jun 23, 6:00AM CDT
--- Carol Gallagher, NEA Partner and Current Board Member, Named Chair -
AGN: 238.28 (-2.31)
Global Migraine Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Allergan, Biofrontera, Mallinckrodt - Research and Markets
BusinessWire - Wed Jun 22, 1:12PM CDT
Research and Markets has announced the addition of the "Migraine - Pipeline Review, H1 2016" report to their offering.
AGN: 238.28 (-2.31)
Impax (IPXL) Stock Declines on Deal to Buy Generic Products
Arpita Dutt - Zacks Investment Research - Wed Jun 22, 9:20AM CDT
Impax's (IPXL) stock declined 11.5% following the company's announcement regarding the acquisition of generic products.
IPXL: 30.62 (+1.27), AGN: 238.28 (-2.31), TEVA: 50.93 (+0.04), AMPH: 16.94 (+0.14)
Asian shares mostly up as investors await more Brexit polls
By TERESA CEROJANO - AP - Tue Jun 21, 10:52PM CDT
MANILA, Philippines (AP) — Asian shares were mostly higher Wednesday, with investors focused on Thursday's vote on Britain's possible withdrawal from the European Union and after relief over U.S. Federal Reserve Chair Janet Yellen's statement that the Fed would remain cautious in raising interest rates.
AGN: 238.28 (-2.31), T: 42.51 (-0.10), OSIS: 58.63 (+0.94), VZ: 55.93 (+0.03), UAL: 42.41 (+0.93)
United and American Science jump, Werner and Impax slump
AP - Tue Jun 21, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
AGN: 238.28 (-2.31), IPXL: 30.62 (+1.27), CP.TO: 174.45 (+0.55), WERN: 23.81 (-0.01), CP: 133.01 (-0.34), ASEI: 37.24 (-0.13), IMPV: 48.14 (+3.38), UAL: 42.41 (+0.93)
Allergan Falls 1.87% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 21, 12:01PM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $230.20 to a high of $238.26. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $234.20 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 238.28 (-2.31)
Impax Signs Definitive Agreements to Acquire Generic Products
PR Newswire - Tue Jun 21, 6:00AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today announced that it has signed definitive agreements with Teva Pharmaceutical Industries Ltd. ("Teva"
and affiliates of Allergan plc ("Allergan" for the acquisition of a broad portfolio of generic products across solid oral, inhalable, injectable and topical dosage forms and the return to Impax of its rights to its pending abbreviated new drug application ("ANDA" for the generic equivalent to Concerta® (methylphenidate hydrochloride) (the "Transaction" for an aggregate purchase price of $586 million.
IPXL: 30.62 (+1.27), AGN: 238.28 (-2.31)
Ultragenyx Appoints Karah Parschauer as Executive Vice President, General Counsel
GlobeNewswire - Mon Jun 20, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has appointed Karah Parschauer as Executive Vice President, General Counsel. In this newly created role, she will be responsible for leading the company's legal, compliance, and corporate governance functions. She will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx's Chief Executive Officer, and will serve on the Executive Leadership Team.
AGN: 238.28 (-2.31), RARE: 52.88 (-0.47)
Allergan Demonstrates a Strong Commitment to America's First Responders Donating Over $1 Million Worth of REFRESH® Eye Drops
PR Newswire - Thu Jul 07, 7:05AM CDT
Allergan plc is pleased to announce that it is leading the effort to alleviate discomfort of dry eye symptoms for America's heroes and has exceeded its goal of donating $1 million worth of REFRESH® eye drops to our nation's first responders. Last summer, Allergan kicked off the REFRESH AMERICA campaign aiming to help everyday heroes alleviate their discomfort from dry eye symptoms brought on by exposure to elements like heat, wind, smoke and dust which are inherent to their work. Every purchase of specially-marked packages in the REFRESH OPTIVE® product line since August 2015 has led to over eighty thousand donations of REFRESH® eye drops to first responder groups nationwide.
AGN: 238.28 (-2.31)
AstraZeneca Skin Drug, Tralokinumab, Rights Licensed to LEO
Arpita Dutt - Zacks Investment Research - Wed Jul 06, 8:39AM CDT
AstraZeneca (AZN) out-licensed global rights to tralokinumab for skin diseases to LEO Pharma.
AGN: 238.28 (-2.31), VRX: 23.09 (-0.16), AZN: 29.97 (-0.14), AMGN: 160.18 (-0.92)
Revance Appoints Industry Leader Julian S. Gangolli to its Board of Directors
BusinessWire - Tue Jul 05, 7:00AM CDT
Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Julian S. Gangolli, President, North America, of GW Pharmaceuticals plc, has been elected to Revance's Board of Directors and will serve as a member of the Audit Committee, effective July 1, 2016.
AGN: 238.28 (-2.31), RVNC: 13.25 (-0.04)
Allergan Receives Positive Opinion Through European Decentralised Procedure For BELKYRA® (Deoxycholic Acid) For Patients With Submental Fullness
PR Newswire Europe - Fri Jul 01, 6:30AM CDT
-- BELKYRA((R)) (deoxycholic acid) expected to be the first non-surgical prescription medicine to treat submental fullness (or double chin) to be authorised in 21 European Union Member States as well as Iceland and Norway --
AGN: 238.28 (-2.31)
New Global Research from Allergan Shows New Attitude to Beauty as Women Seek Confidence Over Youth
PR Newswire Europe - Fri Jul 01, 3:43AM CDT
DUBLIN and MARLOW, England, July 1, 2016 /PRNewswire/ --
AGN: 238.28 (-2.31)
New Global Research From Allergan Shows New Attitude To Beauty As Women Seek Confidence Over Youth
PR Newswire Europe - Tue Jun 28, 6:01AM CDT
-- First and largest of its kind research captures the attitudes of nearly 8,000 women across 16 countries and identifies a new age of beauty confidence(1)
AGN: 238.28 (-2.31)
After Yesterday's Decline of 2.88%, Allergan Offers Investors Better Value
Comtex SmarTrend(R) - Mon Jun 27, 12:18PM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $217.67 to a high of $225.87. Yesterday, the shares fell 2.9%, which took the trading range below the 3-day low of $225.40 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 238.28 (-2.31)
Teva's Cinqaero Gets Positive CHMP View, Decision in 2H16
Arpita Dutt - Zacks Investment Research - Mon Jun 27, 7:10AM CDT
Teva's (TEVA) asthma treatment, Cinqaero, which is already available in the U.S., got a positive CHMP opinion.
AGN: 238.28 (-2.31), PFE: 36.15 (+0.03), TEVA: 50.93 (+0.04), AMPH: 16.94 (+0.14)
Allergan (AGN) Gets FDA Nod for Avycaz Label Expansion
Arpita Dutt - Zacks Investment Research - Fri Jun 24, 8:12AM CDT
Allergan (AGN) is working on expanding the label of several of its approved products.
AGN: 238.28 (-2.31), PFE: 36.15 (+0.03), TEVA: 50.93 (+0.04), AMPH: 16.94 (+0.14)
Why Pfizer (PFE) is a Great Stock to Buy for the Long Run
Maher Syed - Zacks Investment Research - Thu Jun 23, 7:37PM CDT
Pfizer has a great dividend, and it generates an incredibly high level of sales, but here's why else this stock is worth keeping in your portfolio for the long haul.
AGN: 238.28 (-2.31), PFE: 36.15 (+0.03), ANAC: 99.06 (-0.14)
Millendo Therapeutics Appoints New Independent Board Member and Names Chairperson of the Board
BusinessWire - Thu Jun 23, 6:00AM CDT
--- Carol Gallagher, NEA Partner and Current Board Member, Named Chair -
AGN: 238.28 (-2.31)
Global Migraine Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Allergan, Biofrontera, Mallinckrodt - Research and Markets
BusinessWire - Wed Jun 22, 1:12PM CDT
Research and Markets has announced the addition of the "Migraine - Pipeline Review, H1 2016" report to their offering.
AGN: 238.28 (-2.31)
Impax (IPXL) Stock Declines on Deal to Buy Generic Products
Arpita Dutt - Zacks Investment Research - Wed Jun 22, 9:20AM CDT
Impax's (IPXL) stock declined 11.5% following the company's announcement regarding the acquisition of generic products.
IPXL: 30.62 (+1.27), AGN: 238.28 (-2.31), TEVA: 50.93 (+0.04), AMPH: 16.94 (+0.14)
Asian shares mostly up as investors await more Brexit polls
By TERESA CEROJANO - AP - Tue Jun 21, 10:52PM CDT
MANILA, Philippines (AP) — Asian shares were mostly higher Wednesday, with investors focused on Thursday's vote on Britain's possible withdrawal from the European Union and after relief over U.S. Federal Reserve Chair Janet Yellen's statement that the Fed would remain cautious in raising interest rates.
AGN: 238.28 (-2.31), T: 42.51 (-0.10), OSIS: 58.63 (+0.94), VZ: 55.93 (+0.03), UAL: 42.41 (+0.93)
United and American Science jump, Werner and Impax slump
AP - Tue Jun 21, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
AGN: 238.28 (-2.31), IPXL: 30.62 (+1.27), CP.TO: 174.45 (+0.55), WERN: 23.81 (-0.01), CP: 133.01 (-0.34), ASEI: 37.24 (-0.13), IMPV: 48.14 (+3.38), UAL: 42.41 (+0.93)
Allergan Falls 1.87% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 21, 12:01PM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $230.20 to a high of $238.26. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $234.20 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 238.28 (-2.31)
Impax Signs Definitive Agreements to Acquire Generic Products
PR Newswire - Tue Jun 21, 6:00AM CDT
Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today announced that it has signed definitive agreements with Teva Pharmaceutical Industries Ltd. ("Teva"
and affiliates of Allergan plc ("Allergan" for the acquisition of a broad portfolio of generic products across solid oral, inhalable, injectable and topical dosage forms and the return to Impax of its rights to its pending abbreviated new drug application ("ANDA" for the generic equivalent to Concerta® (methylphenidate hydrochloride) (the "Transaction" for an aggregate purchase price of $586 million. IPXL: 30.62 (+1.27), AGN: 238.28 (-2.31)
Ultragenyx Appoints Karah Parschauer as Executive Vice President, General Counsel
GlobeNewswire - Mon Jun 20, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has appointed Karah Parschauer as Executive Vice President, General Counsel. In this newly created role, she will be responsible for leading the company's legal, compliance, and corporate governance functions. She will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx's Chief Executive Officer, and will serve on the Executive Leadership Team.
AGN: 238.28 (-2.31), RARE: 52.88 (-0.47)
